Global Information
회사소개 | 문의

세계의 비알코올성 지방간염(NASH) 치료제 시장 : 산업 분석과 전망

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)

리서치사 Koncept Analytics
발행일 2018년 10월 상품 코드 397981
페이지 정보 영문 75 Pages
가격
US $ 800 ₩ 911,500 PDF by E-mail (Single User License)
US $ 1,100 ₩ 1,253,300 PDF by E-mail (Corporate User License)


세계의 비알코올성 지방간염(NASH) 치료제 시장 : 산업 분석과 전망 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)
발행일 : 2018년 10월 페이지 정보 : 영문 75 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세계의 비알코올성 지방간염(NASH : Non-Alcoholic Steatohepatitis) 치료제 시장에 대해 분석했으며, 질환 개요와 주요 진단·치료 방법, 치료제 시장 동향 전망, 종류별·지역별 동향, 향후 치료제 개발·임상시험 전망, 주요 시장 성장 촉진·억제요인, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 서론

  • 비알코올성 지방간염(NASH)
  • 원인과 증상
  • 진단 방법
  • 치료 방법

제2장 세계의 비알코올성 지방간염(NASH) 시장

  • 세계의 NASH 관련 시장 예측
  • 세계의 NASH 관련 시장 예측 : 약제 클래스별
  • NASH 치료용 오프라벨 의약품 시장 예측

제3장 세계의 NASH 치료제 시장

  • 세계의 NASH 치료제 시장 예측
  • 세계의 NASH 치료제 시장 예측 : 약제 클래스별
  • 세계의 NASH 치료제 시장 예측 : 지역별
  • 세계의 NASH 치료제 시장 : 종류별

제4장 지역별 NASH 시장

  • 미국
  • 유럽
  • 기타

제5장 시장 역학

  • 성장 촉진요인
  • 주요 동향과 발전
  • 해결해야 할 과제

제6장 경쟁 구도

제7장 기업 개요

KSM 17.10.26

Non-alcoholic Steatohepatitis or NASH is a common term for "silent" liver disease and can result into cirrhosis, in which liver is permanently damaged and after a certain point could lead to death. Currently, no specific medicines for NASH exist, but certain specialty drugs are expected to enter the market in the year 2020.

The global NASH drugs market is expected to witness a lucrative growth due the mounting occurrence of NASH, rising healthcare expenditure, increasing obese patient population, unmet medical needs and sedentary lifestyle. The market is trending with rising pharmaceutical R&D expenditures, development of NASH diagnosis methods and biomarkers, progressing drugs under pipeline and intensifying e-commerce pharmaceutical products sales. However, there are some growth hindering factors in the market including lethargic drug approval process, high treatment cost and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to constantly increasing prevalence of various types of liver disease and the local companies engaged in the manufacturing of NASH drugs.

The report "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Gilead Sciences, Inc., Allergan Plc (Tobira), Intercept Pharmaceuticals, Inc., and Genfit SA are being profiled along with their respective financials and growth strategies.

1. Market Overview

  • 1.1 Introduction
  • 1.2 Causes & Symptoms
  • 1.3 Diagnosis
  • 1.4 Treatment

2. Global NASH Market

  • 2.1 Global NASH Drugs Market Value Forecast
  • 2.2 Global NASH Drugs Market Value Forecast by Drug Class
  • 2.3 Global NASH Off-Label Drugs Market Value Forecast

3. Global NASH Therapeutics Market

  • 3.1 Global NASH Therapeutics Market Value Forecast
  • 3.2 Global NASH Therapeutics Market Value Forecast by Drug Type
    • 3.2.1 Global Obeticholic Acid (OCA) Drug Value Forecast
    • 3.2.2 Global Obeticholic Acid (OCA) Drug Value Forecast by Region
    • 3.2.3 Global Cenicriviroc (CVC) Drug Value Forecast
    • 3.2.4 Global Cenicriviroc (CVC) Drug Value Forecast by Region
    • 3.2.5 Global Elafibranor Drug Value Forecast
    • 3.2.6 Global Aramchol Drug Value Forecast
    • 3.2.7 Global MGL-3196 Drug Value Forecast
    • 3.2.8 Global INN-217 Drug Value Forecast
    • 3.2.9 Global VK2809 Drug Value Forecast
  • 3.3 Global NASH Therapeutics Market Value Forecast by Region

4. Regional NASH Market

  • 4.1 The U.S. NASH Therapeutics Market Value Forecast
  • 4.2 Europe NASH Therapeutics Market Value Forecast
  • 4.3 RoW NASH Therapeutics Market Value Forecast

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Mounting Occurrence of NASH
    • 5.1.2 Rising HealthCare Expenditure
    • 5.1.3 Swelling Obese Patient Population
    • 5.1.4 Accelerating Economic Growth
    • 5.1.5 Unmet Medical Needs
    • 5.1.6 Sedentary Lifestyle
  • 5.2 Key Trends & Development
    • 5.2.1 Rising Pharmaceutical R&D Expenditures
    • 5.2.2 Development of NASH Diagnosis Methods and Biomarkers
    • 5.2.3 Progressing Drugs under Pipeline
    • 5.2.4 Intensifying E-Commerce Pharmaceutical Products Sales
  • 5.3 Challenges
    • 5.3.1 Lethargic Drug Approval Process
    • 5.3.2 High Treatment Cost
    • 5.3.3 Associated Business Risk

6. Competitive Landscape

  • 6.1 Global NASH Drugs Market
    • 6.1.1 Key Players - Revenue Comparison
    • 6.1.2 Key Players - Market Cap Comparison
    • 6.1.3 Key Players - Product Portfolio Comparison

7. Company Profiles

  • 7.1 Gilead Sciences, Inc.
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Allergan Plc (Tobira)
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Intercept Pharmaceuticals, Inc.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Genfit SA
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • List of Figures
  • NAFLD Spectrum and Estimated Advancement Risk
  • Potential Phase III NASH Drugs
  • Global NASH Drugs Market Value Forecast (2017-2027)
  • Global NASH Drugs Market Value Forecast by Drug Class (2017/2022/2027)
  • Global NASH Off-Label Drugs Market Value Forecast (2017-2027)
  • Global NASH Therapeutics Market Value Forecast (2020-2027)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2022)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2027)
  • Global Obeticholic Acid (OCA) Drug Value Forecast (2020-2027)
  • Global Obeticholic Acid (OCA) Drug Value Forecast by Region (2027)
  • Global Cenicriviroc (CVC) Drug Value Forecast (2020-2027)
  • Global Cenicriviroc (CVC) Drug Value Forecast by Region (2027)
  • Global Elafibranor Drug Value Forecast (2020-2027)
  • Global Aramchol Drug Value Forecast (2022-2027)
  • Global MGL-3196 Drug Value Forecast (2023-2027)
  • Global INN-217 Drug Value Forecast (2023-2027)
  • Global VK2809 Drug Value Forecast (2023-2027)
  • Global NASH Therapeutics Market Value Forecast by Region (2022)
  • Global NASH Therapeutics Market Value Forecast by Region (2027)
  • The U.S. NASH Therapeutics Market Value Forecast (2022-2027)
  • Europe NASH Therapeutics Market Value Forecast (2022-2027)
  • RoW NASH Therapeutics Market Value Forecast (2022-2027)
  • The U.S. NASH Patient Population (2017-2027)
  • Global HealthCare Expenditure Per Capita (2013-2017)
  • Global Obese Patient Population (2013-2017)
  • Global GDP Per Capita (2013-2017)
  • Global Pharmaceutical R&D Expenditures (2013-2017)
  • Global E-Commerce Pharmaceutical Products Sales (2017-2022)
  • Drugs Approval Process
  • Key Players - Market Cap Comparison (2018)
  • Gilead Sciences Revenues by Business Segments (2017)
  • Gilead Sciences Revenues and Net Income (2013-2017)
  • Gilead Sciences R&D Expenditure (2015-2017)
  • Allergan (Tobira) Net Revenues by Business Segments (2017)
  • Allergan (Tobira) Net Revenues and Net Loss (2013-2017)
  • Allergan (Tobira) R&D Expenditures (2015-2017)
  • Intercept Pharmaceuticals Revenue and Net Loss (2013-2017)
  • Intercept Pharmaceuticals A&P Expenditures (2015-2017)
  • Intercept Pharmaceuticals R&D Expenditures (2015-2017)
  • Genfit Revenues and Net Loss (2013-2017)
  • Genfit R&D Expenditures (2015-2017)

List of Tables

  • NASH Off-Label Therapies (2017)
  • Selected NASH Diagnosis Methods and Biomarkers under Development (2018)
  • Drugs under Development for NASH (2018)
  • NASH Annual Treatment Cost Comparison (2018)
  • Key Players - Revenue Comparison (2017)
  • Key Players - Product Portfolio Comparison (2018)
  • Intercept Pharmaceuticals Product Pipeline (2018)
  • Genfit Product Pipeline (2018)
Back to Top
전화 문의
이용안내
 
BCC Research